Log In
BCIQ
Print this Print this
 

Tedopi (OSE 2101) (formerly EP-2101, EP2101, IDM-2101, Texopi)

  Manage Alerts
Collapse Summary General Information
Company OSE Immunotherapeutics S.A.
DescriptionVaccine containing 10 modified epitopes plus the PADRE universal helper T lymphocyte epitope targeting 5 tumor-associated antigens (TAA)
Molecular Target Not applicable
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase III
Standard IndicationNon-small cell lung cancer (NSCLC)
Indication DetailsSecond- or third-line treatment of stage IIIB/IV non-small cell lung cancer (NSCLC); Treat non-small cell lung cancer (NSCLC) in HLA-A2-positive patients; Treat stage IIB/IIIA non-small cell lung cancer (NSCLC); Treat stage IIIB/IV or recurrent non-small cell lung cancer (NSCLC) in leukocyte antigen (HLA)-A2-positive patients
Regulatory Designation U.S. - Orphan Drug (Treat non-small cell lung cancer (NSCLC) in HLA-A2-positive patients)
PartnerRafa Laboratories Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

4

$33.7M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today